Description: DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. The company's immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips to automate microplate based assays; and ETI Max 3000, an automated microtiter plate analyzer. It also offers molecular diagnostic products LIAISON MDX a thermocycler; and LIAISON IAM, an instrument for amplification of nucleic acids, as well as kits, PCR master mixes, primer pairs, and molecular controls for monitoring oncology and infectious diseases. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, North Americam Central America, South America, and the Asia Pacific. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.
Home Page: diasoringroup.com
Via Crescentino snc
Saluggia,
VC
13040
Italy
Phone:
39 01 614871
Officers
| Name | Title |
|---|---|
| Mr. Carlo Rosa | CEO, GM & Exec. Director |
| Dr. Chen Menachem Even | Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director |
| Mr. Piergiorgio Pedron | Sr. Corp. VP, CFO & Corp. Accounting Documents Officer |
| Mr. Riccardo Fava | Corp. VP of Communication & Investor Relations |
| Mr. Ulisse Spada | Mang. of Corp. Legal Affairs Department |
| Mr. Stefano Ronchi | Sr. Corp. VP of HR |
| Mr. Fabrizio Bonelli | Chief Scientific Officer |
| Mr. Ugo Gay | Sr. Corp. VP of Industrial Operations |
| Mr. Angelo Rago | Pres of Luminex Corp. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 30.581 |
|---|---|
| Trailing PE: | 25.1705 |
| Price-to-Book MRQ: | 4.7288 |
| Price-to-Sales TTM: | 5.562 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3313 |